Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1527-1532

  Tanaka, Kazuhide ^a,b   Morinobu, Shigeru ^a   Ichimura, Mai ^b,c   Asakawa, Akihiro ^d   Inui, Akio ^d   Hosoda, Hiroshi ^e   Kangawa, Kenji ^e   Yamawaki, Shigeto ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Shigasato Hospital   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Body weight; Ghrelin; Hospitalized patient; Leptin; Olanzapine; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FATTY ACID; GHRELIN; GLUCOSE; HYDROCORTISONE; HYPNOTIC SEDATIVE AGENT; LEPTIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DRUG EFFECT; ENERGY METABOLISM; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; JAPANESE; MALE; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; GHRELIN; HEMOGLOBIN A, GLYCOSYLATED; HORMONES; HUMANS; HYDROCORTISONE; LIPIDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 47949101140     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.05.013     Document Type: Article

References (75)

1. Akamizu T., Murayama T., Teramukai S., Miura K., Bando I., Irako T., et al. Plasma ghrelin levels in healthy elderly volunteers: the levels of acylated ghrelin in elderly females correlate positively with serum IGF-1 levels and bowel movement frequency and negatively systolic blood pressure. J Endocrinol 188 (2006) 333-344
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappellwri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
3. Ariyasu H., Takaya K., Tagami T., Ogawa Y., Hosoda K., Akamizu T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86 (2001) 4753-4758
4. Atmaca M., Kuloglu M., Tezcan E., and Ustandag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64 (2003) 598-604
5. Barak Y., Shamir E., Mirecki L., Weizman R., and Aizenberg D. Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol 7 (2004) 165-169
6. Barkan A.L., Dimaraki E.V., Jessup S.K., Symons K.V., Ermolenko M., and Jaffe C.A. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 88 (2003) 2180-2184
7. Brogilo F., Gottero C., Prodam F., Destefanis S., Gauna C., Me E., et al. Ghrelin secretion is inhibited by glucose and insulin-induced hypoglycaemia but unaffected by glucagons and arginine in humans. Clin Endocrinol 61 (2003) 503-509
8. Campfield L.A., Smith F.J., and Burn P. The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm Metab Res 28 (1996) 619-632
9. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl) 7 (2004) 4-18
10. Chan J.L., Bullen J., Lee J.H., Yinnakouris N., and Mantzoros C.S. Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. J Clin Endocrinol Metab 89 (2004) 335-343
11. Coiro V., Sccani-Jotti G., Minelli R., Melani A., Milli B., Manfredi G., et al. Adrenocorticotropin/cortisol and arginine-vasopressin secretory patterns in response to ghrelin in normal men. Neuroendocrinology 81 (2005) 103-106
12. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 46 (2001) 549-555
13. Covell N.H., Weissman E.M., and Essock S.M. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull 30 (2004) 229-240
14. Dallman M.F., La Fleur S.E., Pecoraro N.C., Gomez F., Houshyar H., and Akana S.F. Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 145 (2004) 2633-2638
15. Elimam A., Knutsson U., Bronnegard M., Stierna P., Albertsson-Wikland K., and Marcus C. Variations in glucocorticoid levels within the physiological range affect plasma leptin levels. Eur J Endocrinol 139 (1998) 615-620
16. Epel E., Lapidus R., McEwen B., and Brownell K. Stress may add bite to appetite in women: a laboratory study of stress-induced cortisol and eating behavior. Psychoneuroendoclinology 26 (2001) 37-49
17. Fargerberg B., Hulten L.M., and Hulthe J. Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atheroscrelosis and insulin resistance study. Metabolism 52 (2003) 1460-1463
18. Fontaine K.R., Heo M., Harrigan E.P., Shear C.L., Laskshminarayanan M., Casey D.E., et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101 (2001) 277-288
19. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 60 Suppl 21 (1999) 20-24
20. Gattaz W.F., Diehl A., Geuppert M.S., Hubrich P., Schmitt A., Linde I., et al. Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a double-blind trial. Pharmacopsychiatry 37 (2004) 279-285
21. Greenman Y., Golani N., Gilad S., Yaron M., Limor R., and Stern N. Ghrelin secretion is modulated in a nutrient- and gender-specific manner. Clin Endocrinol 60 (2004) 382-388
22. Harris E., and Barraclough B. Excess mortality of mental disorders. Br J Psychiatry 173 (1998) 11-53
23. Haupt D.W., Luber A., Maeda J., Melson A.K., Schweiger J.A., and Newcomer J.W. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 30 (2005) 184-191
24. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 (2005) 1115-1121
25. Horvath T.L. The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci 8 (2005) 561-565
26. Horvath T.L., Diano S., Sotonyi P., Heiman M., and Tschop M. Ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 142 (2001) 4163-4169
27. Hosoda H., Kojima M., Matsuo H., and Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279 (2000) 909-913
28. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20 (2006) 75-79
29. Ikezaki A., Hosoda H., Ito K., Iwama S., Miura N., and Matsuoka H. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PA-1, but not with leptin, in obese children and adolescents. Diabetes 50 (2002) 3408-3411
30. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2 (2001) 551-560
31. Kamegai J., Tamura H., Shimizu T., Ishii S., Sugihara H., and Oikawa S. Effects of insulin, leptin, and glucagons on ghrelin secretion from isolated perfused rat stomach. Regul Peptides 119 (2004) 77-81
32. Kim B., Kim S.J., Son J.I., and Joo Y.H. Weight change in the acute treatment of bipolar disorder: a naturalistic observational study of psychiatric patients. J Affect Disord 105 (2008) 45-52
33. Kishimoto M., Okimura Y., Nakata H., Kudo T., Iguchi G., Takahashi Y., et al. Cloning and characterization of the 5'-flanking region of the human ghrelin gene. Biochem Biophys Res Commun 305 (2003) 186-192
34. Klok M.D., Jakbsdottir S., and Drent M. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8 (2007) 21-34
35. Kojima M., Hosoda H., Date Y., Nasamitsu M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
36. Kozakowski J., Rabijewski M., and Zgliczynski W. Ghrelin - growth hormone releasing and orexigenic hormone in men declines with age, insulin and with decrease in testosterone concentration. Neuro Endocrinol Lett 29 (2008) 100-106
37. Lambert M., Holzbach R., Moritz S., Postel N., Krausz M., and Naber D. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int Clin Psychopharmacol 18 (2003) 251-260
38. Lambert M., Haro J.M., Novick D., Edgell E.T., Kennedy L., Ratcliffe M., et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-Patient Health Outcomes Study. Acta Psychiatr Scand 111 (2005) 232-243
39. Liberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
40. Makovey J., Naganathan V., Seibel M., and Sambrook P. Gender differences in plasma ghrelin and its relations to body composition and bone -an opposite-sex twin study-. Clin Endocrinol 66 (2007) 530-537
41. Mann K., Rossbach W., Muller M.J., Muller-Seicheneder F., Pott T., Lindle I., et al. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31 (2006) 256-264
42. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161 (2004) 1334-1349
43. McIntyre R.S., McCann S.M., and Kennedy S.H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46 (2001) 273-281
44. Melkersson K.I., Hulting A.L., and Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or psychoses. J Clin Psychatry 61 (2000) 742-749
45. Monti V., Carlsson J.J., Hunt S.C., and Adams T.D. Relationship of ghrelin and leptin hormones with body mass index and waist circumference in a random sample of adults. J Am Diet Assoc 106 (2006) 822-888
46. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., Kangawa K., et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30 (2004) 106-110
47. Newcomer J.W. Antipsychotics medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 suppl 4 (2007) 8-13
48. Newcomer J.W., Selke G., Melson A.K., Gross J., Vogler G.P., and Gagogo-Jack S. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Arch Gen Psychiatry 55 (1998) 995-1000
49. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59 (2002) 337-345
50. Newman S.C., and Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36 (1991) 239-245
51. Palik E., Birkas K.D., Faludi G., Karadi I., and Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 68S1 (2005) S60-S64
52. Park A.J., and Bloom S.R. Neuroendocrine control of food intake. Curr Opin Gastroenterol 21 (2005) 228-233
53. Paton C., Esop R., Young C., and Taylor D. Obesity, dyslipidaemiass and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 110 (2004) 299-305
54. Purnell J.Q., Weigle D.S., Breen P., and Cummings D.E. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 88 (2003) 5747-5752
55. Rigamonti A.E., Pincelli A.I., Corra B., Viarengo R., Bonomo S.M., Galimberti D., et al. Plsma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 175 (2002) R 1-5
56. Ryan M.C.M., Flanagan S., Kinscella U., Keeling F., and Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci 74 (2004) 1999-2008
57. Saari K., Koponen H., Laitinen J., Jokelainen J., Lauren L., Isohanni M., et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 65 (2004) 5470-5550
58. Scheepers F.E., Gespen de Wied C.C., and Kahn R.S. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol 21 (2001) 575-582
59. Schmid D.A., Heid K., Ising M., Uhr M., Weikel J.C., and Steiger A. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but not affect leptin in normal controls. Neuropsychopharmacology 30 (2005) 1187-1192
60. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rossenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159 (2002) 975-981
61. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87 (2002) 240-244
62. Shimada M., Date Y., Mondal M.S., Toshinai K., Fukunaga K., Murakami N., et al. Somatostatin suppress ghrelin secretion from the rat stomach. Biochem Biophys Res Commun 302 (2003) 520-523
63. Shuto Y., Shibasaki T., Otagiri A., Kuriyama H., Ohata H., Tamura H., et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 109 (2002) 1429-1436
64. Sletten I., Cazenave M., and Gershon S. Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. Dis Nerv Syst 28 (1967) 519-522
65. Sturm K., MacIntosh C.G., Parker B.A., Wishart J., Horowitz M., and Chapman I.M. Appetite, food intake, and plasma concentrations of cholecystokinin, ghrelin, and other gastrointestinal hormones in undernourished older women and well-nourished young and older women. J Clin Endocrinol Metab 88 (2003) 3747-3755
66. Tassone F., Broglio F., Destefanis S., Rovere S., Benso A., Gottero C., et al. Neuroendocire and metabolic effects of acute ghrelin administration in human obesity. J Clin Endocrinol Metab 88 (2003) 5478-5483
67. Theisen F.M., Gebhardt S., Bromel T., Otto B., Heldwein W., Heinzel-Gutenbrunner M., et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 112 (2005) 1411-1416
68. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
69. Togo T., Hasegawa K., Miura S., Hosojima K., Shoji M., Kase A., et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology 172 (2004) 230-232
70. Tohen M., Chengappa K.N., Suppes T., Zarate Jr. C.A., Calabrese J.R., Bowden C.L., et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59 (2002) 62-69
71. Vilarrasa N., Vendrell J., Maravall J., Broch M., Estepa A., Megia A., et al. Distribution and determinations of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol 63 (2005) 329-335
72. Woods S.C., Chavez M., Park C.R., Riedy C., Kaiyala K., Richardson R.D., et al. The evaluation of insulin as a metabolic signal influencing behavior via the brain. Neurosci Biobehav Rev 20 (1996) 139-144
73. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 (2001) 5992-5995
74. Yildiz B.O., Suchard M.A., Wong M.L., MaCann S.M., and Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A 101 (2004) 10434-10439
75. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37 (2003) 193-220